8,976 Shares in Halozyme Therapeutics, Inc. $HALO Bought by Teza Capital Management LLC

Key Points

• Teza Capital Management LLC acquired 8,976 shares of Halozyme Therapeutics, valued at approximately $573,000, indicating growing institutional interest in the biopharmaceutical company.
• Halozyme reported earnings of $1.54 per share for the last quarter, significantly surpassing expectations and showcasing a 40.8% increase in revenue year-over-year.
• Insider trading activity saw CEO Helen Torley selling 20,000 shares, reducing her ownership by 2.65%, which raises potential concerns among investors regarding insider sentiment.

Teza Capital Management LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 8,976 shares of the biopharmaceutical company's stock, valued at approximately $573,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Scientech Research LLC raised its stake in shares of Halozyme Therapeutics by 8.9% in the first quarter. Scientech Research LLC now owns 17,533 shares of the biopharmaceutical company's stock worth $1,119,000 after acquiring an additional 1,432 shares during the last quarter. Panoramic Capital LLC raised its stake in shares of Halozyme Therapeutics by 146.7% in the first quarter. Panoramic Capital LLC now owns 135,255 shares of the biopharmaceutical company's stock worth $8,631,000 after acquiring an additional 80,434 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Halozyme Therapeutics in the first quarter worth about $11,636,000. Hancock Whitney Corp raised its stake in shares of Halozyme Therapeutics by 68.7% in the first quarter. Hancock Whitney Corp now owns 203,818 shares of the biopharmaceutical company's stock worth $13,006,000 after acquiring an additional 83,007 shares during the last quarter. Finally, Clark Capital Management Group Inc. raised its stake in shares of Halozyme Therapeutics by 15.1% in the first quarter. Clark Capital Management Group Inc. now owns 205,762 shares of the biopharmaceutical company's stock worth $13,130,000 after acquiring an additional 26,935 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $74.44, for a total transaction of $1,488,800.00. Following the completion of the sale, the chief executive officer owned 733,719 shares of the company's stock, valued at $54,618,042.36. This represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bernadette Connaughton sold 4,000 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $73.68, for a total transaction of $294,720.00. Following the sale, the director directly owned 46,952 shares of the company's stock, valued at $3,459,423.36. This represents a 7.85% decrease in their position. The disclosure for this sale can be found here. Insiders sold 124,000 shares of company stock valued at $7,830,320 over the last quarter. Corporate insiders own 2.40% of the company's stock.

Analyst Ratings Changes

A number of brokerages have weighed in on HALO. Wall Street Zen downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 5th. Morgan Stanley boosted their target price on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an "overweight" rating in a research note on Monday, August 18th. JMP Securities boosted their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a research note on Wednesday, August 6th. JPMorgan Chase & Co. boosted their price target on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. Finally, Zacks Research raised shares of Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics has an average rating of "Hold" and an average target price of $67.11.

Halozyme Therapeutics Trading Down 0.8%

NASDAQ:HALO traded down $0.63 during trading hours on Friday, hitting $76.90. The stock had a trading volume of 1,121,085 shares, compared to its average volume of 1,930,531. Halozyme Therapeutics, Inc. has a one year low of $42.01 and a one year high of $77.60. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. The company has a market cap of $8.99 billion, a price-to-earnings ratio of 17.60, a P/E/G ratio of 0.43 and a beta of 1.19. The business's 50 day moving average is $65.11 and its 200-day moving average is $60.45.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The firm had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. During the same quarter in the prior year, the firm earned $0.91 earnings per share. The business's quarterly revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.